US EditionPublished • loading... • Updated
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom
Summary by ts2.tech
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom
New York, Jan 20, 2026, 15:50 EST — Regular session Gilead Sciences shares slipped 0.2% to $124.68 in afternoon trading, after fluctuating between $122.49 and $126.22 earlier. Bernstein SocGen Group stuck with its Outperform rating and a $135 price target, highlighting Yeztugo as key to Gilead’s 2026 outlook. The firm also suggested investors might be undervaluing the potential impact of re-dosing scheduled for later this year. (Investing.com) T…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
